Hammoud R, Drucker DJ (2023) Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Through these combined actions, enhanced insulin secretion, reduced glucagon, delayed gastric emptying, appetite suppression, and favorable metabolic and cardiovascular effects, semaglutide provides durable glycemic control, substantial weight reduction, and cardiovascular risk reduction in patients with type 2 diabetes and obesity
Having these on hand reduces reliance on less nutritious options when hunger strikes unexpectedly
Ideally, a healthy lifestyle with morning sunlight, a balanced diet, low stress, and adequate sleep would prevent obesity, but for those who are already overweight or obese, medical interventions like GLP1s can provide a different path to weight loss 1m30s